These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11474786)

  • 1. Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.
    Arimori K; Kuroki N; Kumamoto A; Tanoue N; Nakano M; Kumazawa E; Tohgo A; Kikuchi M
    Pharm Res; 2001 Jun; 18(6):814-22. PubMed ID: 11474786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
    Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N; Hosokawa Y; Yokokura T; Awazu S
    Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
    Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
    Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
    Sugiyama Y; Kato Y; Chu X
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
    Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
    Horikawa M; Kato Y; Sugiyama Y
    Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.
    Scott DO; Bindra DS; Stella VJ
    Pharm Res; 1993 Oct; 10(10):1451-7. PubMed ID: 8272406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
    Hamada A; Aoki A; Terazaki H; Ito K; Yokoo K; Sasaki Y; Saito H
    Ther Drug Monit; 2005 Aug; 27(4):536-8. PubMed ID: 16044114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
    Chu XY; Kato Y; Sugiyama Y
    Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
    Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
    Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
    Haaz MC; Rivory LP; Riché C; Robert J
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
    El-Gizawy SA; Hedaya MA
    Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan (CPT-11): a brief overview.
    Rivory LP
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.